P53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells

Cell Death and Differentiation

Volumn 6, Issue 3, 1999, Pages 271-280

  Ruiz Ruiz, María Del Carmen ^a   López Rivas, Abelardo ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Apoptosis; Breast; CD95; CD95L; Genotoxic drugs; p53; Tumor

Indexed keywords

ANTIBODY; DNA; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA; METHOTREXATE; PROTEIN P53; VIRUS PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MINK CELL FOCUS-FORMING VIRUS;

EID: 0001616299     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400490     Document Type: Article

References (54)

1. Barry MA, Behnke CA and Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40: 2353-2362
2. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
3. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849
4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
5. Friesen C, Herr I, Krammer PH and Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Medicine 2: 574-577
6. Müller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR (1997) Drug-induced apoptosis in nepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves ativation of wild-type p53. J. Clin. Inves. 99: 403-413
7. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y and Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243
8. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H and Krammer PH (1992) Purification and molecular cloning of the APO-1 antigen, a new member of the TNF/NGF receptor superfamily: sequence identity with the Fas antigen. J. Biol. Chem. 267: 10709-10715
9. Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178
10. Tanaka M, Suda T, Takahashi T and Nagata S (1995) Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J.14: 1129-1135
11. Nagata S and Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16: 39-43
12. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ and Puck JM (1995) Dominat interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946
13. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH and Moller P (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69: 415-429
14. Keane MM, Ettenberg SA, Lowrey GA, Russell EK and Lipkowitz S (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56: 4791-4798
15. Mizutani Y, Okada Y, Yoshida O, Fukumoto M and Bonavida B (1997) Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 79: 1180-1189
16. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J and Weller M (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother. 44: 55-63
17. Sheard MA, Vojtesek B, Janakova L, Kovarik J and Zaloudik J (1997) Up-regulation of Fas (CD95) in human p53 wild-type cancer cells treated with ionizing radiation. Int. J. Cancer 73: 757-762
18. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E and Radinsky R (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15: 3032-3040
19. Jänicke RU, Sprengart ML, Wati MR and Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273: 9357-9360
20. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K and Sasada M (1998) Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187: 587-600
21. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
22. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA and El-Houseini ME (1994) Induction of p21 (WAF-1/CIP1) during differentiation Oncogene 9: 3389-3396
23. Piette J, Neel H and Maréchal V (1997) Mdm2: keeping p53 under control Oncogene 15: 1001-1010
24. Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
25. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R and Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22: 3551-3555
26. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L and Cho KR (1998) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90: 3988-3992
27. Michalovitz D, Halevy O and Oren M (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680
28. Michael-Michalovitz D, Yehiely F and Oren M (1991) Simian virus 40 can overcome the antiproliferative effect of wild-type p53 in the absence of stable large T antigen-p53 binding. J. Virol. 65: 4160-4168
29. Friedman SL, Shaulian E, Littlewood T, Resnitzky D and Oren M (1997) Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene 15: 63-70
30. Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C and Levrero M (1997) The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc. Natl. Acad. Sci. USA 94: 8162-8167
31. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nature Medicine 2: 1362-1366
32. Herr I, Wilhelm D, Böhler T, Angel P and Debatin K-M (1997) Activation of CD95(APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16: 6200-6208
33. Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky GA and Nel A (1998) The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expresison. J. Immunol. 160: 134-144
34. Izquierdo M, Ruiz-Ruiz MC and Lopez-Rivas A (1996) Stimulation of phosphatidylinositol turnover is a key event for Fas-dependent, activation-induced apoptosis in human T lymphocytes. J. Immunol. 157: 21-28
35. Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG and Gumerlock PH (1997) p53-independent response of a human breast carcinoma xenograft to radio-immunotherapy. Cancer 80: 2529-2537
36. Strasser A, Harris AW, Jacks T and Cory S (1994) DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339
37. Gartenhaus RB, Wang P and Hoffmann P (1996) Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-indepenent pathway. Proc. Natl. Acad. Sci. USA 93: 265-268
38. Woo M, Haken R, Soengas MS, Duncan GS, Shahinian A, Kägi D, Hakem A, McCurrach M, Khoo W, Kaufman SA, Senaldi G, Howard T, Lowe SW and Mak TW (1998) Essential contribution of caspase3/CPP32 to apoptosis and its associated nuclear changes. Genes and Dev. 12: 806-819
39. Droin N, Dubrez L, Eymin B, Renvoizé C, Bréard J, Dimanche-Boitrel MT and Solary E (1998) Upregulation of CASP genes in human tumor cells undergoing etoposide induced apoptosis. Oncogene 16: 2885-2894
40. Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR and Kiefer MC (1997) Interferon-; moduilates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem. 272: 16351-16357
41. Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S and Taniguchi T (1998) An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376: 596-599
42. Schiltz PM, Beutel LD, Nayak SK and Dillman RO (1997) Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J. Immunother. 20: 377-386
43. Tamura T, Aoyama N, Saya H, Haga H, Futami S, Miyamoto S, Koh T, Ariyasu T, Tachi M, Kasuga M and Takahashi R (1995) Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11: 1939-1946
44. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P and Salvadori B (1996) p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 14: 1604-1610
45. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G and Veronesi U (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 85: 965-970
46. Dublin EA, Miles DW, Rubens RD, Smith P and Barnes DM (1997) p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. Int. J. Cancer 74: 605-608
47. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B (1992) Definition of a consensus binding site for p53. Nat. Genet. 1: 45-49
48. Miyashita T and Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299
49. Ludwig RL, Bates S and Vousden KH (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell Biol. 16: 4952-4960
50. Behrmann I, Walczak H and Krammer PH (1994) Structure of the human APO-1 gene. Eur. J. Immunol. 24: 3057-3062
51. Cheng J, Liu C, Koopman WJ and Mountz JD (1995) Characterization of human Fas gene. Exon/intron organization and promoter region. J. Immunol. 154: 1239-1245
52. Sánchez A, Alvarez AM, Benito M and Fabregat I (1996) Apoptosis induced by transforming growth factor-β in fetal hepatocyte primary cultures. J. Biol. Chem. 271: 7416-7422
53. Gong J, Traganos F and Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal. Biochem. 218: 314-319
54. Ruiz-Ruiz MC, Izquierdo M, de Murcia G and López-Rivas A (1997) Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Eur. J. Immunol. 27: 1442-1450